Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 2,407 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dysplasia Mild Clear all

Conditions: Mild Cognitive Impairment
Interventions: Personalized cognitive-sensorimotor VR/MR training, Standard of Care; Other
Lead sponsor: Kessler Foundation; Other
Eligibility: 65 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Mild Traumatic Brain Injury
Interventions: Not listed
Lead sponsor: The Defense and Veterans Brain Injury Center; Federal
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Fort Carson, Colorado • Fort Bragg, North Carolina

Conditions: Atopic Dermatitis
Interventions: ATI-1777 2.0% w/w, ATI-1777 1.0% w/w, ATI-1777 0.5% w/w, Vehicle; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 32
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 29 more

Conditions: Psoriasis
Interventions: SFA002; Drug
Lead sponsor: SFA Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Pompano Beach, Florida • Fargo, North Dakota • Philadelphia, Pennsylvania

Conditions: Cognitive Change, Cognitive Impairment, Mild, Aging
Interventions: Piano Training; Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 65 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Cognitive Impairment, Mild, Dementia, Mild, Alzheimer Disease
Interventions: 18F-AV-1451, C-11 ER-176; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 90 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer, Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), Chronic Wound Care
Interventions: Platelet Rich Plasma; Device
Lead sponsor: Estar Medical dba Medical Technologies, LTD; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Corpus Christi, Texas

Conditions: Diabetic Neuropathies
Interventions: SSR180575, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Mild Persistent Asthma, Uncomplicated
Interventions: Nadolol, Placebo; Drug
Lead sponsor: Invion, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 3
States / cities: St Louis, Missouri • Durham, North Carolina • Houston, Texas

Conditions: Mild Alzheimer's Disease, Mild Cognitive Impairment
Interventions: HPP854, Placebo; Drug
Lead sponsor: High Point Pharmaceuticals, LLC.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Miami, Florida • Durham, North Carolina • High Point, North Carolina

Conditions: Hypertension
Interventions: Saline, QCZ484; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 63
States / cities: Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 58 more

Conditions: Brain Concussion, Mild Traumatic Brain Injury
Interventions: electronic Clinical Decision Support tool for risk stratification of pediatric patients with mTBI; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 5 Years to 18 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atopic Dermatitis Eczema
Interventions: AO+Mist, Placebo; Other
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atopic Dermatitis
Interventions: Q301 Cream, Vehicle; Drug
Lead sponsor: Qurient Co., Ltd.; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorders, Memory Loss
Interventions: Scopolamine (0.4mg), Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alzheimer Disease
Interventions: lecozotan SR (SRA-333); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 30 more

Conditions: Primary Open Angle Glaucoma
Interventions: Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery; Device · Procedure
Lead sponsor: Nova Eye, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Cognitive Change, Cognitive Decline, Cognitive Deterioration, Neurocognitive Deficit
Interventions: BrainCheck Assessment; Device
Lead sponsor: BrainCheck, Inc.; Other
Eligibility: 50 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Palo Alto, California • Multiple Locations, Connecticut • Austin, Texas + 2 more

Conditions: Mild Traumatic Brain Injury
Interventions: Cognitive Assessment, Patient Reported Neurological Outcome Assessments, Blood Draw; Behavioral · Procedure
Lead sponsor: BRAINBox Solutions Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Kansas City, Kansas • Detroit, Michigan • Rochester, New York + 5 more

Conditions: Intellectual Disability, Mild to Moderate, Developmental Disability
Interventions: Ready to Ride - Standard Delivery, Ready to Ride - Peer Support Delivery; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 27 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Durham, New Hampshire

Conditions: Alzheimer's Disease
Interventions: PF-04360365 1 mg/kg, PF-04360365 3 mg/kg, PF-04360365 5 mg/kg, PF-04360365 10 mg/kg; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Glendale, California • Eatontown, New Jersey • Oakhurst, New Jersey

Conditions: Hearing Loss, Sensorineural, Dementia of Alzheimer Type, Amnestic Mild Cognitive Impairment
Interventions: High level of signal manipulation, Low level of signal manipulation; Device
Lead sponsor: Northwestern University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Controlling Mild to Moderate Bleeding During Surgery
Interventions: EVARREST® Fibrin Sealant Patch; Biological
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 28 Days to 17 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama • New York, New York

Conditions: Asthma
Interventions: Fexofenadine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

Cognitive Integrated Motor Training (CM) to Improve Gait and Balance and Reduce Falls in Older Adults With Mild Cognitive Impairment

Deployment Related Mild Traumatic Brain Injury (mTBI)

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

Robot-assisted Cognitive Training for Lonely Older Adults With Mild Cognitive Impairment (MCI)

Tau PET Outcomes With Anti-amyloid Immunotherapies

Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.

Dose-effect of SSR180575 in Diabetic Neuropathy

Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma

Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Utilizing Electronic Clinical Decision Support to Enhance mTBI Care at the Primary Care Point of Entry

Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

Pharmacological Modulation of Brain Oscillations in Memory Processing

Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

Normative Database and Test-Retest Reliability for BrainCheck Assessments

HEAD Injury Serum Markers and Multi-modalities for Assessing Response to Trauma

Comparing the Impact of Peer Support vs. Staff-Delivered Transportation Interventions for Young Adults With Intellectual and Developmental Disabilities.

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Characterizing Variability in Hearing Aid Outcomes in Among Older Adults With Alzheimer's Dementia

The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma